J Trent Magruder1, Dariush Elahi, Dana K Andersen. 1. Department of Surgery, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Abstract
OBJECTIVES: Although half of all patients with pancreatic cancer are diabetic at the time of diagnosis, it remains unclear whether the diabetes associated with pancreatic cancer is a cause or an effect of the malignancy. METHODS: Epidemiologic studies were reviewed, the geographic prevalence of diabetes and the incidence of pancreatic cancer were examined, and clinical and laboratory studies were reviewed. RESULTS: Long-standing diabetes increases the risk of pancreatic cancer by 40% to 100%, and recent-onset diabetes is associated with a 4- to 7-fold increase in risk, such that 1% to 2% of patients with recent-onset diabetes will develop pancreatic cancer within 3 years. Treatment of diabetes or morbid obesity decreases the risk of pancreatic cancer, and metformin therapy decreases the risk due to both its antidiabetic and antineoplastic effects. Recent-onset diabetes associated with pancreatic cancer likely represents secondary or type 3 diabetes. The discrimination of type 3 diabetes from the more prevalent type 2 diabetes may identify the high-risk subgroup of diabetic patients in whom potentially curable pancreatic cancer may be found. CONCLUSIONS: Type 2 and type 1 diabetes mellitus increase the risk of pancreatic cancer with a latency period of more than 5 years. Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients.
OBJECTIVES: Although half of all patients with pancreatic cancer are diabetic at the time of diagnosis, it remains unclear whether the diabetes associated with pancreatic cancer is a cause or an effect of the malignancy. METHODS: Epidemiologic studies were reviewed, the geographic prevalence of diabetes and the incidence of pancreatic cancer were examined, and clinical and laboratory studies were reviewed. RESULTS: Long-standing diabetes increases the risk of pancreatic cancer by 40% to 100%, and recent-onset diabetes is associated with a 4- to 7-fold increase in risk, such that 1% to 2% of patients with recent-onset diabetes will develop pancreatic cancer within 3 years. Treatment of diabetes or morbid obesity decreases the risk of pancreatic cancer, and metformin therapy decreases the risk due to both its antidiabetic and antineoplastic effects. Recent-onset diabetes associated with pancreatic cancer likely represents secondary or type 3 diabetes. The discrimination of type 3 diabetes from the more prevalent type 2 diabetes may identify the high-risk subgroup of diabeticpatients in whom potentially curable pancreatic cancer may be found. CONCLUSIONS: Type 2 and type 1 diabetes mellitus increase the risk of pancreatic cancer with a latency period of more than 5 years. Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients.
Authors: Miroslav Vujasinovic; Bojan Tepes; Jana Makuc; Sasa Rudolf; Jelka Zaletel; Tjasa Vidmar; Maja Seruga; Bostjan Birsa Journal: World J Gastroenterol Date: 2014-12-28 Impact factor: 5.742
Authors: María P Torres; Satyanarayana Rachagani; Vinee Purohit; Poomy Pandey; Suhasini Joshi; Erik D Moore; Sonny L Johansson; Pankaj K Singh; Apar K Ganti; Surinder K Batra Journal: Cancer Lett Date: 2012-04-01 Impact factor: 8.679
Authors: Chen Yuan; Douglas A Rubinson; Zhi Rong Qian; Chen Wu; Peter Kraft; Ying Bao; Shuji Ogino; Kimmie Ng; Thomas E Clancy; Richard S Swanson; Megan J Gorman; Lauren K Brais; Tingting Li; Meir J Stampfer; Frank B Hu; Edward L Giovannucci; Matthew H Kulke; Charles S Fuchs; Brian M Wolpin Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544